X

Drug Profile

Apomorphine - Takeda

Alternative Names: Ixense; Spontane; TAK 251; Uprima

Latest Information Update: 23 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pentech Pharmaceuticals
Developer Pentech Pharmaceuticals; Takeda
Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
Mechanism of Action Dopamine D2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Parkinson's disease
New Molecular Entity No

Highest Development Phases

Marketed Erectile dysfunction
Discontinued Neurogenic bladder

Most Recent Events

07 Feb 2013 Discontinued - Phase-I for Erectile dysfunction in Japan (Sublingual)
02 Feb 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
14 Aug 2006 No development reported - Phase-I for Erectile dysfunction in Japan (Sublingual)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com